Vayu Sleep Announces Breakthrough Personalized Mask Technology to Transform Global Sleep Apnea Treatment
Today, a new and disruptive player in the Sleep Health Industry has seen the Light of Day.
Vayu Sleep announces its formation and development of a new and innovative technology set to revolutionize how Sleep Apnea is treated on a global scale.
The newly formed company, led by sleep medicine entrepreneur David Walton, is developing a fully custom-fit sleep mask, expected to launch later this year as the first customized CPAP mask on the US market.
Vayu Sleep's aim is to address the critical challenge that has plagued the industry for decades: Patients quitting the gold standard treatment due to uncomfortable masks.
"Our mission at Vayu Sleep is simple but powerful – to change people’s lives through effective CPAP therapy," says David Walton, who previously co-founded Respire Medical.
At the core of Vayu Sleep’s innovation is advanced facial scanning technology that enables each mask to be tailored to the individual - improving comfort, fit, and overall treatment success. The scan takes seconds on a smartphone, with a custom-manufactured mask delivered directly to the patient’s door within days.
Shark Tank featured scanning technology
The revolutionary technology comes through a strategic partnership with THEMAGIC5, known for their personalized swim goggles that gained national attention on Shark Tank in 2021 and secured a million dollar investment from Mark Cuban and Robert Herjavec. Their proprietary Optimal Fitting Technology measures thousands of unique facial data points to ensure an optimal seal and fit.
“Every face is unique, and we believe every product should match the individual - not the other way around. With Vayu Sleep we will leverage our precision technology to dramatically improve comfort and effectiveness of CPAP masks,” says Rasmus Barfred, co-founder of THEMAGIC5.
An estimated 30 million Americans suffer from sleep apnea, and the condition is linked to increased risk of heart disease, stroke, type 2 diabetes and cognitive decline. Estimates suggest that 80 pct. of patients are undiagnosed, and among those receiving treatment, compliance rates are alarmingly low and drop-off rates are too high.
"We're not just creating a more comfortable mask, we're potentially adding years to patients' lives by helping them stay with a therapy we know works,” says David Walton.
The mask is in preliminary testing with a full product launch scheduled for Q4 2025. Pre-orders expected to open in the late summer.
Media Contact
David Walton, CEO, Vayu Sleep
Email: hello@vayusleep.com
For additional information about Vayu Sleep, visit www.vayusleep.com